CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Market Closed 09-04 16:00:00 EDT

15.52

+0.93

+6.37%

盘后15.52

+0.000.00%

19:30 EDT

High15.96	Low14.28	Vol1.50M
Open14.49	D1 Closing14.59	Amplitude11.51%
Mkt Cap888.68M	Tradable Cap645.69M	Total Shares57.26M
T/O23.15M	T/O Rate3.59%	Tradable Shares41.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":15.52,"timestamp":1788552000000,"preClose":14.59,"halted":0,"volume":1495360,"hourTrading":{"tag":"盘后","latestPrice":15.52,"preClose":15.52,"latestTime":"19:30 EDT","volume":18189,"amount":282272.12,"timestamp":1788564603266,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06374228923920491,"floatShares":41603800,"shares":57260500,"eps":-0.83475,"marketStatus":"Market Closed","change":0.93,"latestTime":"09-04 16:00:00 EDT","open":14.49,"high":15.96,"low":14.28,"amount":23145783.21472,"amplitude":0.115147,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.83475,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":14.59,"preHourTrading":{"tag":"盘前","latestPrice":14.49,"preClose":14.59,"latestTime":"09:29 EDT","volume":8522,"amount":122569.224526,"timestamp":1788528599922,"change":-0.1,"changeRate":-0.006854,"amplitude":0.082557},"postHourTrading":{"tag":"盘后","latestPrice":15.52,"preClose":15.52,"latestTime":"19:30 EDT","volume":18189,"amount":282272.12,"timestamp":1788564603266,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6234371441662085,"impliedVol":1.0975,"impliedVolPercentile":0.4204},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"2665355200","title":"Climb Bio Price Target Raised to $30.00/Share from $26.00 by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2665355200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665355200?lang=en_us&edition=fundamental","pubTime":"2026-09-05 01:52","pubTimestamp":1788544320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664358323","title":"Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664358323","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664358323?lang=en_us&edition=fundamental","pubTime":"2026-09-04 23:17","pubTimestamp":1788535063,"startTime":"0","endTime":"0","summary":"Climb Bio's  data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was \"positive,\" Wedbush analysts said in a Friday note.Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.Some investors were looking for a more clear-cut \"winner\" between Climb Bio and Jade Biosciences  in their nephropathy clinical trials, Wedbush said.Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.Wedbush kept its outperform rating and a $25 price target on the stock.Shares of the company were up nearly 8% in Friday trading.Price: 15.75, Change: +1.16, Percent Change: +7.95","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JBIO","CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840383","title":"U.S. Research Roundup-Ciena Corp, Docusign, Snowflake","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664840383?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:08","pubTimestamp":1788505701,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, SnowflakeSept 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ciena...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nL4N44W0I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZS","PATH","ALGS","CURV","SAIA","AMBA","DOCU","NETL","TSN","AKAM","COST","PCAR","PHM","SFNC","IONS","NNN","ASAN","CBNK","CLYM","INDS","SRHR","FERG","GWRE","LEN","OBT","DAT","MARS","RTH","O","WPC","CIEN","VSXY","SNOW","PCG","COTG","AQWA","FSTA","IOT","FCPT","DNTH","HP","ORA","CTRI","SNOY","PTEN","PL","BP","CLIM","FLNC","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338502","title":"Climb Bio Inc : Btig Raises Target Price to $32 from $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338502?lang=en_us&edition=fundamental","pubTime":"2026-09-04 11:36","pubTimestamp":1788492998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W007:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805690","title":"Climb Bio price target raised to $25 from $21 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805690?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:50","pubTimestamp":1788454211,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Climb Bio (CLYM) to $25 from $21 and keeps an Outperform rating on the shares after the company shared Phas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-25-from-21-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-25-from-21-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580804","title":"Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580804","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580804?lang=en_us&edition=fundamental","pubTime":"2026-09-03 23:23","pubTimestamp":1788449030,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $24.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808356","title":"Climb Bio price target raised to $40 from $23 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808356?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:25","pubTimestamp":1788445516,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Climb Bio (CLYM) to $40 from $23 and keeps an Overweight rating on the share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-40-from-23-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-40-from-23-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387220","title":"U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387220","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664387220?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:06","pubTimestamp":1788440813,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Polestar Automotive, NvidiaSeptember 3 (Reuters)-The S&P 500 and the Nasdaq 100 indexes looked set for a subdued open on Thursday following mixed corporate ea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL6N44V0TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VT","AVL","LU0323240290.USD","LU0823434583.USD","LU1145028129.USD","LU1645745479.HKD","LU1629891620.HKD","LU0316494557.USD","LU2286300806.USD","LU2047632596.USD","LU0417517546.SGD","LU0353189680.USD","LU2592432038.USD","LU2089283258.USD","LU1116320737.USD","LU0303823156.USD","LU2458330169.SGD","LU0320765059.SGD","SG9999002224.SGD","LU1989772840.SGD","REMX","LU1815336760.USD","FAI","LU0820561818.USD","LU1674673428.USD","LU1127390331.HKD","07388","LU1974910355.USD","LU2543165471.USD","LU0348723411.USD","LU0289739343.SGD","LU2087621335.USD","AMAL","LU1316542783.SGD","LU0106261372.USD","CHAT","BK4614","LU1951198990.SGD","NVDB","LU1162221912.USD","LU0057025933.USD","LU2552382215.SGD","LU0823421333.USD","LU0648001328.SGD","SG9999000418.SGD","LU2168563687.JPY","IE00B775SV38.USD","CIBR","DLTH","LU0306807586.USD","LU1803068623.USD","BK4116","LU1720051108.HKD","SOXQ","LU0553294199.USD","LU2430703095.HKD","LITP","LU0109392836.USD","LU2361044865.SGD","LU2637965513.SGD","LU0672654240.SGD","LU1989764748.USD","SG9999015358.SGD","CLYM","LU1992135472.HKD","LU0109391861.USD","IE00BK4W5L77.USD","IE00BMPRXN33.USD","ESUM","LU1400636491.USD","LU2092937148.SGD","LU1674673691.USD","LU2417539215.USD","LU0267386448.USD","NVDG","XLK","SGXZ31699556.SGD","NULC","LU1934455863.HKD","LU0738911758.USD","LU0158827948.USD","GDMN","LU2089284900.SGD","GAMR","LU1861215975.USD","IE00BD4GTW91.USD","LU0642271901.SGD","BK4097","LU0306806265.USD","LU1868837565.USD","LU0266512473.USD","LU1721428933.USD","LU0784383803.USD","LU0310800379.SGD","IE000Q6AESB8.SGD","LU0511384066.AUD","LU1815333072.USD","LU1861219969.SGD","LU1861220033.SGD","IE0003U64NQ7.SGD","LU0353189763.USD","BK4512","GOAU","LU1791710582.SGD","LU1267930573.SGD","LU1267930490.SGD","LU0234570918.USD","BK4533","LU0289961442.SGD","GFI","LU0011850046.USD","LU0128525929.USD","LU0308772762.SGD","LU0957808578.USD","LU1366192091.USD","LU2552382132.HKD","IE00BZ1G4Q59.USD","LU2326559502.SGD","BK4539","LU1868838027.USD","LU2403377893.USD","LU1223083913.SGD","LU2023251221.USD","LU2125909759.SGD","LU1400636657.SGD","LU1119994496.HKD","LU1935043536.SGD","LU0788109121.HKD","LU2491050154.USD","IE0034235303.USD","LU0203201768.USD","LU1043141396.HKD","AVGG","LU0724617625.USD","2NVD.UK","BK4109","07788","USD","LU0289960550.SGD","LU0330918003.SGD","SMH","IE00BMPRXQ63.HKD","LU0868494617.USD","SG9999014575.USD","BK4529","ARTY","LU0158827781.USD","LU2360108059.USD","LU0006306889.USD","BK4515","LU2279689827.SGD","LU2452424414.USD","BK4554","LU2168564222.USD","LU2487616109.SGD","LU1992135399.USD","LU0345769631.USD","LU2054465674.USD","LU0496367417.USD","LU1691799644.USD","LU1670710588.SGD","IE00BVYPNQ40.USD","LU2413666699.HKD","09388","BK4139","LU0444973449.USD","LU0154236417.USD","LU0170899867.USD","IE00BJLML261.HKD","LU0124676726.USD","LU2077746001.SGD","CRM","SG9999015945.SGD","BK4550","LU1935042215.USD","HK0000320223.HKD","LU0130518102.USD","LU2471134952.CNY","LU2063271972.USD","LU0345774391.USD","LU2931357623.SGD","LU0612318971.USD","LU2756315318.SGD","LU1496350171.SGD","SOXY","IE00BJJMRY28.SGD","IE00BVYPNP33.GBP","LU1223082519.USD","SETM","BK4543","BK4527","LU0256863902.USD","SG9999015341.SGD","LU2462611646.USD","CPB","CLOU","LU0053666078.USD","LU0211327993.USD","AVGU","LU2413666426.HKD","LU0823421416.USD","LU2210149790.SGD","AUMI","LU0130103400.USD","LU1035775433.USD","LU2471134879.HKD","LU2361045086.USD","NVIW.SI","LU0210536198.USD","IE00BZ199S13.USD","LU1232071149.USD","NVYY","IE00B5949003.HKD","IE0004445239.USD","LU2746668974.SGD","LU1823568750.SGD","SG9999001440.SGD","LU1642822529.SGD","LU0345770993.USD","LU0266013472.USD","LU0466842654.USD","SMHX","LU0786609619.USD","LU2602419157.SGD","LU2756315664.SGD","SAVGOmain","TRUM","LU0251132253.USD","IE00B3M56506.USD","BK4559","LU0096362180.USD","LU2764262908.HKD","LU0476273544.USD","LU1301847155.USD","LU0949170772.SGD","ABFL","LU2360107168.USD","CHPX","HAKY","LU0942090050.USD","LU1261432733.SGD","LU1084165304.USD","IE00B19Z3B42.SGD","PSNY","SG9999017495.SGD","LU1670711123.USD","LU0965508806.USD","LU0081259029.USD","AVGO","IE0009G5SDU7.USD","LU2083900584.USD","IE00BFSS8Q28.SGD","LU2360106780.USD","LU2461242641.AUD","LU2720916845.USD","LU1023059493.AUD","LU1066051811.HKD","IE0004091025.USD","CRMG","IE000YTNTUN2.SGD","LU0708994859.HKD","NVDU","LU2242649171.HKD","LU2471134523.USD","LU1670711040.USD","LU0354030438.USD","LU1633808545.USD","LU2148611432.USD","SLVP","MDCX","IE00BJTD4N35.SGD","LU0820561909.HKD","BK4135","BK4141","IE00BDCRKT87.USD","LU0143863198.USD","BK4094","LU1366333091.USD","IE00BGHQF631.EUR","LU0980610538.SGD","LU1496350502.SGD","LU1880398471.USD","BK4522","LU2290526834.HKD","LU1066053197.SGD","IE00B1BXHZ80.USD","HK0000304797.USD","LU0477156953.USD","LU2028103732.USD","HK0000819398.USD","LU2462591350.SGD","LU2125154778.USD","LU0061474705.USD","IE00B5TLWC47.USD","VSXY","LU0788108826.HKD","IE00BVYPNW00.USD","ADBG","HK0000914660.USD","IE00BK4W5M84.HKD","LU0029864427.USD","IE00B64PRP62.GBP","LU1670710661.SGD","LU1064131342.USD","CGGO","SG9999014898.SGD","AVGC","LU0994945656.USD","IE00BFSS7M15.SGD","IE00B3S45H60.SGD","AFK","LU0965509010.AUD","LU0320765646.SGD","LU1983260115.SGD","LU2750360641.GBP","SPTE","LU0654597011.USD","NOW","LU1670627923.USD","LU0256863811.USD","LU2125154935.USD","GLDN","LU2237957811.SGD","BX","LU1037948897.HKD","LU1868836591.USD","LU2237443895.HKD","CLOD","LU0127658192.USD","IE00BKVL7J92.USD","GPZ","LU2420271590.USD","LU2272731600.USD","BK4575","LU2360032135.SGD","NVDY","SNOY","LU2237443549.SGD","LU0708995401.HKD","IE00B4YYXB79.USD","LU1144417596.USD","LU0310799852.SGD","LU2125909916.SGD","IE000ITXATA3.USD","IE00BYQQ9H92.USD","ADBE","IE00BQXX3C00.GBP","NVII","LIMI","LU0345780281.USD","BK4598","LU2168564495.EUR","LU2168564065.EUR","LU2244417387.USD","LU2211814178.USD","LU2357305700.SGD","LU0075056555.USD","LU2095319765.USD","BK4570","LU0347712357.USD","LU2250418816.HKD","SGXZ51526630.SGD","IE00B4JS1V06.HKD","LU1880398554.USD","NVC","LU0957791311.USD","TRFK","LU2491049909.HKD","HPE","LU0310800965.SGD","LU0094547139.USD","LU0477156797.USD","LU2237957902.USD","LU0784385170.HKD","LU1069347547.HKD","LU1868836914.USD","LU0052756011.USD","IE00B775H168.HKD","LU1201861165.SGD","BK4588","LU2097344431.USD","HPEL","LU1116320901.HKD","SG9999001424.SGD","SNVD.UK","LU0251142724.SGD","ALBG","LU0557290698.USD","LU1623119135.USD","LU2111349929.HKD","LU1037948541.HKD","LU2498475776.HKD","GDX","LU0528227936.USD","LU1121112475.USD","LU0787776722.HKD","LU1430597077.USD","AVGW","IE00BLSP4452.SGD","IE00BLSP4239.USD","AUAU","BK4566","LU2023250330.USD","LU0823434740.USD","DIPS","ESLG","IE00BKDWB100.SGD","LU0056508442.USD","LU0820562030.AUD","BK4535","LU2473716301.USD","GB00BDT5M118.USD","BK4538","BK4567","BK4099","LU0719512351.SGD","IE00B19Z9Z06.USD","DAT","LU0882574139.USD","SGXZ23171101.USD","IE00BD6J9T35.USD","LU2462157665.USD","LU0300736062.USD","IE00BN29S564.USD","LU0069063385.USD","LU1400636574.HKD","LU2361044949.HKD","XDAT","LU1852331112.SGD","LU1003077747.HKD","IETC","IE00B3SWFQ91.USD","LU2133065610.SGD","LU0048573561.USD","IE00BJJMRX11.SGD","LU2125909593.SGD","IE00BDGV0183.EUR","BK4607","BK4592","LU0265550359.USD","LU0456854461.SGD","LU2065169927.USD","LU2954938101.SGD","LU1814569148.SGD","IE00BYXW3230.USD","LU1571399168.USD","LU0251131958.USD","AVGX","LU0174119429.USD","LU0545039389.USD","LU2471134796.USD","LU1223082196.USD","IE00BD4GTT62.SGD","LU1923623000.USD","IE00B894F039.SGD","LU1236620834.HKD","LU2506951792.HKD","LU0354030511.USD","LU0661504455.SGD","LU1670756490.USD","HK0000532082.HKD","LU2211815571.USD","LU2764263039.SGD","LU0823414551.USD","LU2456880835.USD","BK4532","LU2430703251.USD","BK4587","TDIV","LU1102505929.USD","CNEQ","BK4585","LU2048586759.USD","SG9999014567.USD","LU0889566641.SGD","CGDG","IE00BKPKM429.USD","LU2430703178.SGD","LU2087625088.SGD","LU2125909247.SGD","LU2381873111.SGD","WISE","LU1244550221.USD","LU1244550577.SGD","EFIV","IE00BD4GTV84.USD","LU0203345920.USD","LU0861579265.USD","BK4081","LU2860962120.EUR","SG9999018857.SGD","LU2264538146.SGD","LU0726765562.USD","LU2092627202.USD","LU0689472784.USD","IE000KEQY171.SGD","LU0868494708.USD","NWMX","IE00B42XCP33.USD","LU0225283273.USD","LU0795875169.SGD","LU0215105999.USD","LU2249611893.SGD","LU0321505868.SGD","IE00BHPRN162.USD","LU1548497426.USD","IE0004086264.USD","NOWX","HK0000320264.USD","IE0034235188.USD","LU2210150020.SGD","SNOU","LU2097344357.USD","SG9999001143.SGD","ILIT","LU1878469433.USD","LU1988902786.USD","AU","BK4017","FDTX","NVD3.UK","IE0009356076.USD","BK4505","LU1935042488.USD","LU2108987350.USD","SG9999014914.USD","LU0426412945.USD","LU2999663052.SGD","CLSE","LU1043141123.HKD","LU0278409577.USD","LU0265550946.USD","SG9999014542.SGD","IE0034235295.USD","IE000W1ABFV2.USD","IE00BQXX3F31.USD","LU0368265764.SGD","LU0724618789.USD","LU0965509101.SGD","LU1923622291.USD","LU2265009873.SGD","SNOW","LU2360107325.USD","LU1732799900.SGD","LU0395794307.EUR","LU0345780521.USD","SG9999003800.SGD","FTEC","NVDS","SG9999018865.SGD","LU1699723380.USD","LU0006061336.USD","LU2394011477.USD","LU2347655156.SGD","LU0096364046.USD","BK4023","LU2041044095.USD","LU2463028550.USD","SG9999015952.SGD","BK4561","IE00BZ9MQY76.HKD","SG9999014906.USD","BK4503","LU1951200564.SGD","IE00B19Z9505.USD","LU1989772923.USD","BK4549","LU0072462426.USD","LU0210528500.USD","BK4122","LU1934455277.USD","LU0640476718.USD","SG9999004303.SGD","LU0274383776.USD","NEM","LU1066051498.USD","AGMI","LU0498741890.SGD","LU2237443382.USD","LU0612318385.USD","LU1435385759.SGD","LU0342679015.USD","LU0077335932.USD","IE00BWXC8680.SGD","LU2552382058.USD","LU2355687059.USD","INTU","LU2168564149.EUR","LU0494093205.USD","LU2237443465.HKD","HK0000306701.USD","LU1720051017.SGD","NVDA","LU1235294995.USD","LU0079474960.USD","IE00BDRTCR15.USD","PCG","LU0198837287.USD","IE00BFXG0V08.USD","SNPE","LU1934455194.USD","LU0985481810.HKD","LU2213496289.HKD","IE00B19Z8W00.USD","LU0630314457.HKD","SG9999002232.USD","JGRO","LU0345774631.USD","LU1035773651.USD","LU2106854487.HKD","LU0498741114.HKD","LU1917777945.USD","ANV","BK4581","LU0426417589.USD","LU1989764664.SGD","LU0321505439.SGD","IE00BJTD4V19.USD","LU0689626769.HKD","IE00BN8TJ469.HKD","LU1868837136.USD","LU0792757196.USD","TTXU","LU2322448791.USD","ROM","LU0323239441.USD","SHOC","NVDS.UK","IE00B19Z3581.USD","AAUM","LU1236620750.USD","LU0345769128.USD","SGXZ81514606.USD","NEMG","AVS","LU1551013342.USD","LU0390134368.USD","LU2750360997.AUD","LU0949170426.SGD","LU2092937221.SGD","NVD","IE00B3PB1722.GBP","HMY","SG9999014880.SGD","LU2237438978.USD","LU1551013425.SGD","NVDX","METV","RARE","AGOX","LU1804176565.USD","LU1868836757.USD","LU1923622614.USD","IE00B19Z8X17.USD","LU1712237335.SGD","LU0979878070.USD","BK4551","LU1267930730.SGD","LU2236285917.USD","NVDO","LU0345768740.USD","BK4170","LU2272731865.HKD","USXF","LU1839511570.USD","LU2746668461.USD","SG9999015978.USD","LU0061474960.USD","LU0784385840.USD","LU1280957306.USD","LU0345780950.USD","LU0742534661.SGD","LU0082616367.USD","LU0912757837.SGD","LU0444971666.USD","LU1718418525.SGD","SG9999014559.SGD","IE00B3QW5Z07.USD","LU2294711713.HKD","LU1153585028.USD","LU0943347566.SGD","LU0133085943.USD","IDRV","FMTL","IE00BMPRXR70.SGD","LU0080751232.USD","LU0061475181.USD","LU2347655073.USD","BK4605","LU2491050071.SGD","BK4528","VGT","LU2272731782.SGD","LU1102505762.USD","LU0097036916.USD","LU0648000940.SGD","LIT","LU0211328371.USD","LU0225771236.USD","NVD2.UK","AIPI","SGDM","LU1670628061.USD","IE00BGHQF748.EUR","LU0048584097.USD","LU0225284248.USD","LU0130102774.USD","BK4534","IE00BGHQDM52.EUR","BK4211","LU0964807845.USD","LU1267930227.SGD","NVDL","ADBU","LU0130517989.USD","LU0345781412.USD","LU1242518857.USD","BK4548","LU1244550494.USD","LU0303821028.USD","LU2247934214.USD","LU2458330243.SGD","LU2764263203.CNY","LU2237443622.USD","BK4212","BK4608","LU0203202063.USD","LU2433249047.HKD","LU1732800096.USD","LU0965509283.SGD","LU1821325948.USD","LU2462591277.SGD","PSP","LU0138981039.USD","IE00BVYPNV92.GBP","LU0143863784.USD","LU2100268510.USD","LU2505996509.AUD","LU2065170008.USD","BK4545","SG9999015986.USD","LU2065171402.SGD","LU0323591593.USD","IE00B1XK9C88.USD","LU1046421795.USD","TEK","LFGY","LU2271345857.HKD","LU0683600562.USD","LU1778281490.HKD","LU0107464264.USD","LU0823414478.USD","LU0276348264.USD","LU0889565833.HKD","CGBL","LU0143551892.USD","IE0005OL40V9.USD","IXN","LU0187121727.USD","LU1069344957.HKD","LU2357125470.USD","LU0472753341.HKD","NVDW","LU0345770308.USD","LU2298321311.HKD","THMR","LU1861214812.USD","BK4579","LU1791710400.SGD","LU0203347892.USD","LU1914381329.SGD","LU2346227817.USD","LU2237443978.SGD","LU2317271919.USD","LU2505996681.GBP","BK4612","TTEQ","LU3102509885.SGD","IE00BYV24P56.USD","3NVD.UK","LU1935043023.USD","NOWL","SGXZ80539844.SGD","HK0000914686.HKD","LU0784384876.USD","LU1323610961.USD","LU0300736492.USD","IE0001KFT4U8.USD","IE00B7KXQ091.USD","LU0985320562.USD","IE0002270589.USD","LU1267930813.SGD","LU2896262040.SGD","LU0234572021.USD","AIFD","LU1202635105.USD","LU1803068979.SGD","LU0795875086.SGD","IE00BQXX3D17.EUR","SOXX","LU1868837300.USD","PRVT","SGXZ99366536.SGD","HK0000304805.HKD","CMAG","LU2322448957.HKD","LU0070217475.USD","LU2191332357.HKD","LU0788109477.HKD","LU0128525689.USD","LU1429558221.USD","LU0157215616.USD","LU0055631609.USD","LU0210533765.USD","LU1242518931.SGD","SG9999011175.SGD","LU2023250843.SGD","NVDQ","BK4613","LU2023250504.SGD","LU1861127337.USD","LU0314104364.USD","09788","ALB","BAI","IE00B19Z9P08.USD","LU1935042991.SGD","IE0004445015.USD","LU0266512127.USD","IE00BMCWC346.EUR","LU1066051225.USD","HK0000306685.HKD","LU1883866441.USD","LU2242650005.HKD","NVDD","SNVDAmain","TYLG","IE00BBT3K403.USD","LU2449327464.USD","LU1201861249.SGD","LU0345768153.USD","ILDR","LU2089985449.USD","LU0175139822.USD","LU2065171311.SGD","LU0238689110.USD","LU1979441026.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871981","title":"Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871981","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871981?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:54","pubTimestamp":1788436486,"startTime":"0","endTime":"0","summary":"Climb Bio  said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.Shares of the company were up 7% in Thursday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664760688","title":"Climb Bio - Announces Positive Phase 1 Data for Clym116 in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664760688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664760688?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664087606","title":"Climb Bio - Phase 2 Navigate-2 Trial Ongoing; Initial Data Expected H1 2027, Phase 3 Initiation in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664087606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664087606?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1DM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664065876","title":"Climb Bio - Clym116 Well-Tolerated with no Serious Adverse Events or Dose-Limiting Toxicities","url":"https://stock-news.laohu8.com/highlight/detail?id=2664065876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664065876?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1DM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664756848","title":"Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664756848","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664756848?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:12","pubTimestamp":1788365551,"startTime":"0","endTime":"0","summary":"Climb Bio's  CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.Oppenheimer kept its outperform rating and $18 price target for Climb Bio.Price: 14.62, Change: -0.21, Percent Change: -1.38","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663002534","title":"Climb Bio's Upcoming CLYM116 Data Could Support Longer Dosing, Strong Potency, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663002534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663002534?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:54","pubTimestamp":1788191674,"startTime":"0","endTime":"0","summary":"Climb Bio's  upcoming CLYM116 data could show strong drug activity, longer-lasting effects and potential dosing every eight to 12 weeks, which would strengthen the drug's position against rivals, Oppenheimer said in a note Monday.The investment firm said it expects Thursday's phase 1 update to show how different doses affect IgA levels and how long the treatment effect lasts.A 60% to 70% drop in IgA at relatively low doses would support its view that CLYM116 may be more potent than competing drugs, Oppenheimer said.CLYM116 may also provide longer-lasting effects by clearing the APRIL protein more effectively, while its ability to use higher doses could further extend the treatment benefit, according to the note.Oppenheimer has an outperform rating and $18 price target for Climb Bio.Price: 14.17, Change: -0.40, Percent Change: -2.75","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661522069","title":"Climb Bio is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2661522069","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661522069?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:15","pubTimestamp":1787566500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660746423","title":"Climb Bio Price Target Maintained with a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2660746423","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660746423?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:56","pubTimestamp":1787144160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488079","title":"U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660488079?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:16","pubTimestamp":1786954612,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell TechnologiesAug 17 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DLTR","DUK","DCH","AMLX","URAN","DAVE","HON","RSPS","XLE","ELS","DELL","ESS","CHRD","AEP","EXE","AVBP","BMRN","CCAP","CRWD","APA","DNTH","CPT","AHR","PXE","ABBV","CVX","TDV","AMAT","APP","FHLC","BYND","BCSF","COP","DVN","FANG","CHPS","AVB","EOG","EQT","ALAB","ELVN","TINY","AMTM","BILT","CLYM","EAT","RDVY","TGT","CBRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141812","title":"Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141812","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141812?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:33","pubTimestamp":1786710787,"startTime":"0","endTime":"0","summary":"Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trialA Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio.No","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3SxKqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659018789","title":"Truist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659018789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659018789?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:26","pubTimestamp":1786587965,"startTime":"0","endTime":"0","summary":"In a report released on August 11, Danielle Brill from Truist Financial maintained a Buy rating on Climb Bio, with a price target of $25.00. The co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933738","title":"Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933738?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:36","pubTimestamp":1786361818,"startTime":"0","endTime":"0","summary":"In a report released on August 7, Yatin Suneja from Guggenheim reiterated a Buy rating on Climb Bio, with a price target of $35.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.0652},{"period":"1month","weight":0.2446},{"period":"3month","weight":0.4711},{"period":"6month","weight":1.1616},{"period":"1year","weight":5.6609},{"period":"ytd","weight":2.88}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.090224},{"month":4,"riseRate":0.8,"avgChangeRate":0.28834},{"month":5,"riseRate":0.6,"avgChangeRate":0.068848},{"month":6,"riseRate":0.4,"avgChangeRate":-0.017955},{"month":7,"riseRate":0.6,"avgChangeRate":0.043539},{"month":8,"riseRate":0.4,"avgChangeRate":0.108179},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.082035},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}